1. Topical cyclosporine a 0.05% eyedrops in the treatment of vernal keratoconjunctivitis - randomized placebo-controlled trial.
- Author
-
Keklikci U, Dursun B, and Cingu AK
- Subjects
- Administration, Ophthalmic, Adolescent, Child, Conjunctivitis, Allergic diagnosis, Female, Humans, Male, Ophthalmic Solutions, Prospective Studies, Time Factors, Treatment Outcome, Turkey, Young Adult, Conjunctivitis, Allergic drug therapy, Cyclosporine administration & dosage, Immunosuppressive Agents administration & dosage
- Abstract
Background: Vernal keratoconjunctivitis (VKC) is a chronic, bilateral inflammation of the conjunctiva that mostly affects children and young adult males. Management of VKC is primarily aimed at reducing symptoms and preventing serious vision threatening sequelae., Objectives: To assess the efficacy of topical cyclosporine A (CsA) 0.05% on the signs and symtomps in the management of VKC., Material and Methods: This is a placebo-controlled, randomized prospective study. Sixty-two patients with VKC were included in this study. Patients were randomly assigned (1 : 1) to treatment with topical 0.05% CsA eyedrops or a placebo (artificial tears) for a period of 4 weeks, 4 times daily. Ocular signs and symptoms were in all patients scored at entry and at the end of 4 weeks., Results: When pre-treatment mean signs and symptoms scores were compared in both groups, there was no significant difference (p > 0.05). However, mean post-treatment scores as regards signs and symptoms were found to be lower in cyclosporine group than those in placebo group (p < 0.001). No side effects of the treatment with CsA 0.05% eyedrops were observed., Conclusions: It was found that topical CsA 0.05% eyedrops were safe and effective in the treatment of patients with VKC.
- Published
- 2014
- Full Text
- View/download PDF